STOCK TITAN

Vanda Pharmaceuticals Inc - VNDA STOCK NEWS

Welcome to our dedicated news page for Vanda Pharmaceuticals (Ticker: VNDA), a resource for investors and traders seeking the latest updates and insights on Vanda Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vanda Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vanda Pharmaceuticals's position in the market.

Rhea-AI Summary
Vanda Pharmaceuticals to participate in H.C. Wainwright Global Investment Conference on September 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.1%
Tags
none
-
Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) reported Q2 2023 total revenues of $46.1 million, with a focus on HETLIOZ® and Fanapt® sales. The company provided an update on pipeline advancements and regulatory plans, including positive results for Fanapt® in bipolar disorder and pursuing FDA approvals for HETLIOZ® in insomnia and jet lag disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.05%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
-
Rhea-AI Summary
Vanda Pharmaceuticals to participate in Digestive Disease Week 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.51%
Tags
earnings
Vanda Pharmaceuticals Inc

Nasdaq:VNDA

VNDA Rankings

VNDA Stock Data

236.48M
52.05M
5.32%
92.21%
5.22%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Washington

About VNDA

vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.